{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:24:27Z","timestamp":1790792667031,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Multiple sclerosis (MS) is a chronic disease of the central nervous system that disproportionately affects women, with typical onset during reproductive age. Several disease\u2010modifying therapies (DMTs) are FDA\u2010approved to slow disease progression, but are not indicated for use during pregnancy. Our objective was to describe trends over time (2010\u20132019) in monthly point prevalence of DMT use among reproductive\u2010age women, overall and by generic name.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study used administrative claims data from the US during 2009\u20132019 to identify women age 15\u201344 with MS and continuous insurance coverage for \u226512\u2009months. DMTs were identified using prescription fills and procedural claims for alemtuzumab, daclizumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta, mitoxantrone, natalizumab, ocrelizumab, and teriflunomide. Monthly prevalent use was defined as \u22651\u2009days' supply of a DMT in the month. Age\u2010 and region\u2010standardized monthly prevalence was estimated nonparametrically.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 42\u2009281 reproductive\u2010aged women over 818\u2009179 person\u2010months, DMT use increased from a minimum monthly prevalence of 49.3% (February, 2011) to a maximum of 58.7% (April, 2019). In 2010, prevalence of injectable DMTs was 43.1% compared to 2.5% for oral DMTs; by 2014, however, oral DMTs (26.5%) surpassed injectable DMTs (23.7%) as the most common route of administration. In the most recent data available (December, 2019), the most common DMTs were dimethyl fumarate, glatiramer acetate, and fingolimod.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>DMT use among reproductive\u2010aged women has rapidly evolved during the past decade. Collaborative treatment decision making between women with MS and clinicians may help optimize MS care and improve DMT uptake during reproductive years.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5411","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:44:38Z","timestamp":1643352278000},"page":"481-487","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Trends in the use of disease\u2010modifying therapies among reproductive\u2010aged women with multiple sclerosis in the United States from 2010 to 2019"],"prefix":"10.1002","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0974-8539","authenticated-orcid":false,"given":"Emilie D.","family":"Duchesneau","sequence":"first","affiliation":[{"name":"Department of Epidemiology University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-8685","authenticated-orcid":false,"given":"Alan C.","family":"Kinlaw","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Outcomes and Policy University of North Carolina School of Pharmacy  Chapel Hill North Carolina USA"},{"name":"Cecil G. Sheps Center for Health Services Research University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Jonsson Funk","sequence":"additional","affiliation":[{"name":"Department of Epidemiology University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pate","sequence":"additional","affiliation":[{"name":"Department of Epidemiology University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1108-0689","authenticated-orcid":false,"given":"Jennifer L.","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Epidemiology University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-018-0846-2"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005347"},{"key":"e_1_2_8_5_1","first-page":"1034912","article-title":"Pregnancy and the use of disease\u2010modifying therapies in patients with multiple sclerosis: benefits versus risks","volume":"2016","author":"Alroughani R","year":"2016","journal-title":"Mult Scler Int"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006384"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1885367"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01367-1"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S288296"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2002.8.6.469"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.523670"},{"key":"e_1_2_8_12_1","first-page":"258","volume-title":"Modern Epidemiology","author":"Greenland S","year":"2008"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.22.12.1394"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511430704"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211006499"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4735"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.003"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/21556660.2020.1721507"},{"key":"e_1_2_8_19_1","unstructured":"Medicaid and CHIP Payment and Access Commission.MACPAC Fact Sheet: Medicaid's Role in Financing Maternity Care.https:\/\/www.macpac.gov\/wp-content\/uploads\/2020\/01\/Medicaid%E2%80%99s-Role-in-Financing-Maternity-Care.pdf 2020."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420987031"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2010.16.9.703"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5411","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5411","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T04:53:44Z","timestamp":1693112024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/pds.5411"],"URL":"https:\/\/doi.org\/10.1002\/pds.5411","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"2021-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}